You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

The Emerging Receptor Science in the Management of Schizophrenia

  • Authors: Christoph Correll, MD; Diana Perkins, MD
  • CME Released: 6/10/2021; Reviewed and Renewed: 9/14/2022
  • Valid for credit through: 9/14/2023
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This activity is intended for psychiatrists and primary care physicians.

The goal of this activity is to increase knowledge of how new scientific findings related to the pathophysiology of schizophrenia are resulting in new therapies for schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Roles of different receptor types in schizophrenia
    • Potential utility of trace amine-associated receptor 1 (TAAR1) activation in the management of schizophrenia
  • Have greater competence related to
    • Recognizing the limitations of current treatments


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Faculty

  • Christoph Correll, MD

    Professor of Psychiatry and Molecular Medicine
    Zucker School of Medicine
    Hofstra/Northwell
    Glen Oaks, New York
    Professor of Child and Adolescent Psychiatry
    Charité University of Medicine
    Berlin, Germany

    Disclosures

    Disclosure: Christoph Correll, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Acadia; Alkermes; Allergan; Angelini; Gedeon Richter; IntraCellular Therapies; Janssen/J&J; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mitsubishi Tanabe Pharma; Mylan; Neurocrine; Noven; Otsuka; Pfizer; Recordati; Rovi; Sumitomo Dainippon; Sunovion; Supernus; Takeda; Teva
    Served as a speaker or a member of a speakers bureau for: Angelini; Gedeon Richter; Janssen/J&J; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Sumitomo Dainippon; Otsuka; Recordati; Sunovion
    Received grants for clinical research from: Janssen; Takeda
    Owns stock, stock options, or bonds from: LB Pharma
    Other: DSMB member or chair: Lundbeck; Relmada; ROVI; Teva

  • Diana Perkins, MD

    Professor
    Department of Psychiatry
    Director of Early Psychosis Interventions-North Carolina Consultants
    University of North Carolina School of Medicine
    Chapel Hill, North Carolina

    Disclosures

    Disclosure: Diana Perkins, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alkermes
    Received grants for clinical research from: Boehringer Ingelheim

Editors

  • Lisette Arnaud-Hevi, PhD

    Medical Education Director, Medscape, LLC 

    Disclosures

    Disclosure: Lisette Arnaud-Hevi, PhD, has disclosed no relevant financial relationships. 

  • Walid Amara, MD

    Medical Education Director, WebMD Global, LLC 

    Disclosures

    Disclosure: Walid Amara, MD, has disclosed the following relevant financial relationships: Served as an advisor or consultant for: Biotronix; Servier. Served as a speaker or a member of a speakers bureau for: Bayer HealthCare; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol Myers Squibb Company; LivaNova; MEDA; Medtronic, Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Physiomed; St. Jude, Servier  

  • Christin Melton, ELS

    Scientific Content Manager, Medscape, LLC 

    Disclosures

    Disclosure: Christin Melton, ELS, has disclosed no relevant financial relationships. 

CME Reviewer

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Disclosure: Hazel Dennison, DNP, RN, FNP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

The Emerging Receptor Science in the Management of Schizophrenia

Authors: Christoph Correll, MD; Diana Perkins, MDFaculty and Disclosures

CME Released: 6/10/2021; Reviewed and Renewed: 9/14/2022

Valid for credit through: 9/14/2023

processing....

Educational Impact Challenge

The goal of this activity is to increase knowledge of how new scientific findings related to the pathophysiology of schizophrenia are resulting in new therapies for schizophrenia.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.